Product Development Solutions: Data-Driven, Evidence-Based

GNS Healthcare develops solutions for leading biopharmaceutical, diagnostic, consumer product, and medical device companies, discovering which products work, how they work, and for whom.

We discover predictive biomarker signatures to stratify patients in clinical trials; we unravel mechanisms of drug efficacy and combination therapies; and we discover new therapeutic intervention points for conditions representing unmet medical needs.

We have experience developing solutions for complex, heterogeneous diseases such as cancer, auto-immune diseases, including rheumatoid arthritis (RA), asthma, and inflammatory bowel disease (IBD), and neurological disorders, including Parkinson’s, multiple sclerosis (MS), and Alzheimer’s.

Biomarkers for Patient Selection in Clinical Trials

Discover the optimal set of biomarkers from multiple layers of molecular and clinical data to predict patient responses to your drug and stratify patients in clinical trials.

Real World Example

Discovery of Predictive Biomarkers in Clinical Trials

In collaboration with a leading global pharmaceutical company, GNS Healthcare identified predictive biomarkers of response for an oncology drug in early clinical development. From genotype, gene expression and patient outcome data, REFS™ identified candidate markers, which our collaborators are utilizing in further clinical trials.

Mechanism of Efficacy and Combination Therapies

Build REFS™ models from pre- and post-treatment data to discover the pathways and networks, through which drugs are driving clinical endpoints and simulate the effects of combination therapies.

Real World Example

Mechanism of Action and Combination Therapies for Marketed Cancer Drugs

In collaboration with the National Cancer Institute (NCI), GNS is analyzing gene expression and growth inhibition data for well-known anti-cancer drugs, measured across a broad panel of human cancer cell lines. GNS is building models to discover the mechanisms of action of the drugs and identify potential targets for combination therapies.
Read the Press Release here

Drivers of Disease Progression and Target Discovery

Learn mechanistic models directly from multiple layers of longitudinal molecular and clinical data and conduct simulations to discover optimal therapeutic targets.

Real World Example

Discovery of Novel Personalized Drug Targets from Patient Data

In collaboration with Biogen Idec, GNS Healthcare identified novel therapeutic targets for the one-third of Rheumatoid Arthritis (RA) patients who are non-responsive to anti-TNF therapy. Using genetic, gene expression and clinical outcome data from 77 patients receiving anti-TNF therapy, REFS™ identified intervention points that improved patient outcomes, uncovering both known drug targets and novel intervention points.
Read the PLoS Computatational Biology paper here